Insider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells 1,367 Shares of Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Eric Swayze sold 1,367 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $32.31, for a total transaction of $44,167.77. Following the completion of the sale, the executive vice president now owns 48,017 shares in the company, valued at $1,551,429.27. This represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Eric Swayze also recently made the following trade(s):

• On Thursday, January 16th, Eric Swayze sold 7,154 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $32.84, for a total value of $234,937.36.
• On Tuesday, November 12th, Eric Swayze sold 1,194 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $37.92, for a total transaction of $45,276.48.

Ionis Pharmaceuticals Trading Down 3.8 %

IONS traded down $1.23 on Friday, hitting $31.40. The company had a trading volume of 1,155,625 shares, compared to its average volume of 1,612,974. The business's fifty day simple moving average is $34.88 and its 200 day simple moving average is $39.79. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86. Ionis Pharmaceuticals, Inc. has a 12-month low of $31.03 and a 12-month high of $52.34. The company has a market cap of $4.96 billion, a PE ratio of -12.87 and a beta of 0.35.

Hedge Funds Weigh In On Ionis Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of IONS. Nicollet Investment Management Inc. lifted its position in Ionis Pharmaceuticals by 1.5% in the third quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company's stock worth $817,000 after buying an additional 294 shares during the last quarter. Amalgamated Bank raised its stake in shares of Ionis Pharmaceuticals by 3.1% in the third quarter. Amalgamated Bank now owns 9,957 shares of the company's stock valued at $399,000 after acquiring an additional 300 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Ionis Pharmaceuticals by 83.9% in the 3rd quarter. GAMMA Investing LLC now owns 664 shares of the company's stock worth $27,000 after acquiring an additional 303 shares during the last quarter. Itau Unibanco Holding S.A. boosted its stake in shares of Ionis Pharmaceuticals by 40.9% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company's stock worth $43,000 after purchasing an additional 314 shares during the period. Finally, Bleakley Financial Group LLC grew its holdings in Ionis Pharmaceuticals by 2.1% during the 3rd quarter. Bleakley Financial Group LLC now owns 16,678 shares of the company's stock valued at $668,000 after purchasing an additional 338 shares during the last quarter. Hedge funds and other institutional investors own 93.86% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently commented on IONS. Wells Fargo & Company decreased their price objective on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating on the stock in a research report on Thursday, November 7th. StockNews.com cut Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday, November 12th. William Blair reaffirmed an "outperform" rating on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. Needham & Company LLC restated a "buy" rating and issued a $60.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $70.00 price objective on shares of Ionis Pharmaceuticals in a research report on Wednesday, January 15th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Ionis Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $60.65.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.